http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/CG+Oncology+to+Present+at+Upcoming+Investor+Conferences+in+June/26566287.html <p align="justify">DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President &amp; Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:</p> <p align="justify"><strong>Jefferies Global Healthcare Conference </strong><br/>Date: Wednesday, June 3, 2026<br/>Presentation Time: 10:30-11:00 AM ET<br/>Location: New York, New York</p> <p align="justify"><strong>Goldman Sachs 47th Annual Global Healthcare Conference </strong><br/>Date: Tuesday, June 9, 2026<br/>Presentation Time: 2:40-3:15 PM ET<br/>Location: Miami, Florida</p> <p align="justify">Interested parties http://www.streetinsider.com/Press+Releases/CG+Oncology+to+Present+at+Upcoming+Investor+Conferences+in+June/26566287.html Thu, 28 May 2026 16:05:00 -0400 CGON O.61534501 http://www.streetinsider.com/Press+Releases/CG+Oncology+to+Present+at+Upcoming+Investor+Conferences+in+June/26566287.html <p align="justify">DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President &amp; Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:</p> <p align="justify"><strong>Jefferies Global Healthcare Conference </strong><br/>Date: Wednesday, June 3, 2026<br/>Presentation Time: 10:30-11:00 AM ET<br/>Location: New York, New York</p> <p align="justify"><strong>Goldman Sachs 47th Annual Global Healthcare Conference </strong><br/>Date: Tuesday, June 9, 2026<br/>Presentation Time: 2:40-3:15 PM ET<br/>Location: Miami, Florida</p> <p align="justify">Interested parties http://www.streetinsider.com/Press+Releases/CG+Oncology+to+Present+at+Upcoming+Investor+Conferences+in+June/26566287.html Thu, 28 May 2026 16:05:00 -0400 CGON O.61534501 http://www.streetinsider.com/Globe+Newswire/CG+Oncology+to+Present+at+Upcoming+Investor+Conferences+in+June/26566287.html <p align="justify">DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President &amp; Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:</p> <p align="justify"><strong>Jefferies Global Healthcare Conference </strong><br/>Date: Wednesday, June 3, 2026<br/>Presentation Time: 10:30-11:00 AM ET<br/>Location: New York, New York</p> <p align="justify"><strong>Goldman Sachs 47th Annual Global Healthcare Conference </strong><br/>Date: Tuesday, June 9, 2026<br/>Presentation Time: 2:40-3:15 PM ET<br/>Location: Miami, Florida</p> <p align="justify">Interested parties http://www.streetinsider.com/Globe+Newswire/CG+Oncology+to+Present+at+Upcoming+Investor+Conferences+in+June/26566287.html Thu, 28 May 2026 16:05:00 -0400 CGON O.61534501 http://www.streetinsider.com/Globe+Newswire/CG+Oncology+to+Present+at+Upcoming+Investor+Conferences+in+June/26566287.html <p align="justify">DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President &amp; Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:</p> <p align="justify"><strong>Jefferies Global Healthcare Conference </strong><br/>Date: Wednesday, June 3, 2026<br/>Presentation Time: 10:30-11:00 AM ET<br/>Location: New York, New York</p> <p align="justify"><strong>Goldman Sachs 47th Annual Global Healthcare Conference </strong><br/>Date: Tuesday, June 9, 2026<br/>Presentation Time: 2:40-3:15 PM ET<br/>Location: Miami, Florida</p> <p align="justify">Interested parties http://www.streetinsider.com/Globe+Newswire/CG+Oncology+to+Present+at+Upcoming+Investor+Conferences+in+June/26566287.html Thu, 28 May 2026 16:05:00 -0400 CGON O.61534501 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CG+Oncology%2C+Inc.+++++++++For%3A+May+20/26546218.html si-local-file:///var/storage/secattach/20260526/26546218.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CG+Oncology%2C+Inc.+++++++++For%3A+May+20/26546218.html Tue, 26 May 2026 08:00:00 -0400 CGON O.61534501 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CG+Oncology%2C+Inc.+++++++++For%3A+May+20/26546218.html si-local-file:///var/storage/secattach/20260526/26546218.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CG+Oncology%2C+Inc.+++++++++For%3A+May+20/26546218.html Tue, 26 May 2026 08:00:00 -0400 CGON O.61534501 http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Press+Releases/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html <ul type="disc"><li style="list-style-position:inside; text-align:center;"><em>Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC</em><br/><br/></li><li style="list-style-position:inside; text-align:center;"><em>Last year’s awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA</em><br/><br/></li></ul> <p align="justify">SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a http://www.streetinsider.com/Globe+Newswire/SUO-CTC+and+CG+Oncology+Announce+Award+Recipients+of+the+Second+Annual+Non-Muscle+Invasive+Bladder+Cancer+%28NMIBC%29+Research+Fellowship+Award/26517531.html Tue, 19 May 2026 08:00:00 -0400 A.19718279 A.25255803 A.29114199 CGON O.01951358 O.03960701 O.38675779 O.61534501 http://www.streetinsider.com/New+Coverage/Wolfe+Research+Starts+CG+Oncology+%28CGON%29+at+Peerperform/26516349.html (Updated - May 19, 2026 5:32 AM EDT) <p>Wolfe Research analyst Kalpit Patel initiates coverage on CG Oncology (NASDAQ: CGON) with a Peerperform rating.</p><p>The analyst comments "The stock has appreciated ~150% over the last year, and while we are optimistic on creto’s approvability in HR BCG-UR NMIBC, we are softer on its early launch vs. consensus. 1. We think creto’s product profile is slightly differentiated from Inlexzo’s in HR BCG-UR NMIBC and sufficient to drive meaningful sales in the longterm after a potential approval ('27E) based on Ph3 BOND-003 C. Near term, however, we expect uptake to be tempered by Inlexzo’s http://www.streetinsider.com/New+Coverage/Wolfe+Research+Starts+CG+Oncology+%28CGON%29+at+Peerperform/26516349.html Tue, 19 May 2026 05:32:54 -0400 CGON http://www.streetinsider.com/Analyst+Comments/Wolfe+Research+Starts+CG+Oncology+%28CGON%29+at+Peerperform/26516349.html (Updated - May 19, 2026 5:32 AM EDT) <p>Wolfe Research analyst Kalpit Patel initiates coverage on CG Oncology (NASDAQ: CGON) with a Peerperform rating.</p><p>The analyst comments "The stock has appreciated ~150% over the last year, and while we are optimistic on creto’s approvability in HR BCG-UR NMIBC, we are softer on its early launch vs. consensus. 1. We think creto’s product profile is slightly differentiated from Inlexzo’s in HR BCG-UR NMIBC and sufficient to drive meaningful sales in the longterm after a potential approval ('27E) based on Ph3 BOND-003 C. Near term, however, we expect uptake to be tempered by Inlexzo’s http://www.streetinsider.com/Analyst+Comments/Wolfe+Research+Starts+CG+Oncology+%28CGON%29+at+Peerperform/26516349.html Tue, 19 May 2026 05:32:54 -0400 CGON http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+Rating+on+CG+Oncology+%28CGON%29/26511763.html <p>UBS analyst David Dai reiterated a Buy rating and $90.00 price target on CG Oncology (NASDAQ: CGON).</p><p>The analyst commented, "CGON reported initial results for the Phase 2 CORE-008 Cohort CX evaluating efficacy and safety of cretostimogene (creto) in combination with Gemcitabine (Gem) in patients with HR BCG-unresponsive/-exposed NMIBC. Notably, creto+Gem demonstrated high initial efficacy with 96% HG-EFS at 3- months and ~90% HF-EFS at 6-months by Kaplan-Meier estimates in the ITT population with short follow-up (median 6.6 months). Additionally, creto+Gem showed 92% anytime CR (24/26) in the efficacy evaluable population and ~86% in the ITT population (24/28) for patients with http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+Rating+on+CG+Oncology+%28CGON%29/26511763.html Mon, 18 May 2026 10:17:28 -0400 CGON